Dr. Martens plc

LSE:DOCS Stock Report

Market Cap: UK£772.6m

Dr. Martens Management

Management criteria checks 3/4

Dr. Martens' CEO is Ije Nwokorie, appointed in Jan 2025, has a tenure of less than a year. total yearly compensation is £303.00K, comprised of 49.8% salary and 50.2% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth £263.76K. The average tenure of the management team and the board of directors is 3.6 years and 3.3 years respectively.

Key information

Ije Nwokorie

Chief executive officer

UK£303.0k

Total compensation

CEO salary percentage49.83%
CEO tenureless than a year
CEO ownership0.03%
Management average tenure3.6yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017

Jun 18
Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017

Some Investors May Be Willing To Look Past Dr. Martens' (LON:DOCS) Soft Earnings

Jun 15
Some Investors May Be Willing To Look Past Dr. Martens' (LON:DOCS) Soft Earnings

Dr. Martens (LON:DOCS) May Have Issues Allocating Its Capital

Apr 15
Dr. Martens (LON:DOCS) May Have Issues Allocating Its Capital
author-image

Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26

Strategic focus on premium positioning, demand planning, and cost reductions aims to enhance revenue, margins, and profitability.

Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%

Dec 06
Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%

Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year

Dec 01
Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year

Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet

Sep 21
Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet

Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?

Aug 20
Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?

Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger

Jul 20
Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger

There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings

Jun 19
There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings

Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%

May 21
Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%

The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested

Mar 27
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested

Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet

Mar 06
Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet

Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price

Feb 08
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price

Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market

Jan 21
Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market

Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156

Jan 03
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156

Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156

Dec 13
Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156

Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation

Oct 12
Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation

Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)

Sep 13
Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)

Returns on Capital Paint A Bright Future For Dr. Martens (LON:DOCS)

Jul 12
Returns on Capital Paint A Bright Future For Dr. Martens (LON:DOCS)

A Look At The Intrinsic Value Of Dr. Martens plc (LON:DOCS)

Jun 02
A Look At The Intrinsic Value Of Dr. Martens plc (LON:DOCS)

Dr. Martens (LON:DOCS) Is Investing Its Capital With Increasing Efficiency

Feb 25
Dr. Martens (LON:DOCS) Is Investing Its Capital With Increasing Efficiency

Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 34% Undervaluation?

Dec 17
Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 34% Undervaluation?

The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested

Oct 02
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested

Dr. Martens (LON:DOCS) Knows How To Allocate Capital Effectively

Jul 04
Dr. Martens (LON:DOCS) Knows How To Allocate Capital Effectively

CEO Compensation Analysis

How has Ije Nwokorie's remuneration changed compared to Dr. Martens's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 30 2025n/an/a

UK£5m

Dec 30 2024n/an/a

UK£17m

Sep 30 2024n/an/a

UK£29m

Jun 30 2024n/an/a

UK£49m

Mar 31 2024UK£57kn/a

UK£69m

Dec 31 2023n/an/a

UK£86m

Sep 30 2023n/an/a

UK£103m

Jun 30 2023n/an/a

UK£116m

Mar 31 2023UK£67kn/a

UK£129m

Dec 31 2022n/an/a

UK£153m

Sep 30 2022n/an/a

UK£177m

Jun 30 2022n/an/a

UK£179m

Mar 31 2022UK£65kn/a

UK£181m

Dec 31 2021n/an/a

UK£118m

Sep 30 2021n/an/a

UK£54m

Jun 30 2021n/an/a

UK£44m

Mar 31 2021UK£11kn/a

UK£35m

Compensation vs Market: Ije's total compensation ($USD410.00K) is below average for companies of similar size in the UK market ($USD1.55M).

Compensation vs Earnings: Ije's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Ije Nwokorie (55 yo)

less than a year
Tenure
UK£303,000
Compensation

Mr. Onyeije Ogueri Nwokorie, also known as Ije, is CEO & Director at Dr. Martens Limited since January 06, 2025. He was Chief Brand Officer at Dr. Martens plc since February 01, 2024. He is Independent Non...

Leadership Team

NamePositionTenureCompensationOwnership
Onyeije Nwokorie
CEO & Executive Directorless than a yearUK£303.00k0.034%
£ 263.8k
Giles Robert Wilson
CFO & Director1.2yrsUK£1.78m0.020%
£ 156.6k
Geert Peeters
Chief Operating Officer7.1yrsno datano data
Graham Calder
Chief Technology Officerno datano datano data
Bridget Jolliffe
Chief People Officerno datano datano data
Sean O'Neill
Chief Digital Officer7.3yrsno datano data
Derek Chan
President of APAC5.8yrsno datano data
Adam Meek
Chief Product Officer3.6yrsno datano data
Jennifer Somer
President of Americas3.7yrsno datano data
Mike Stopforth
President of EMEA2.2yrsno datano data
Tuze Mekik
Director of Sustainabilityno datano datano data
Carla Murphy
Chief Brand Officerno datano datano data
3.6yrs
Average Tenure
55yo
Average Age

Experienced Management: DOCS's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Onyeije Nwokorie
CEO & Executive Directorless than a yearUK£303.00k0.034%
£ 263.8k
Giles Robert Wilson
CFO & Director1.2yrsUK£1.78m0.020%
£ 156.6k
Robert Hanson
Independent Non-Executive Directorless than a yearUK£1.00kno data
Andrew Harrison
Independent Non-Executive Director2.2yrsUK£68.00k0.0079%
£ 61.3k
Benoit Vauchy
Non-Independent Non-Executive Directorless than a yearno datano data
Ian Rogers
Independent Non-Executive Director4.5yrsUK£68.00k0.0021%
£ 16.2k
Robyn Perriss
Independent Non-Executive Director4.5yrsUK£96.00k0.010%
£ 79.4k
Tara Alhadeff
Representative Non-Independent Non-Executive Director4.5yrsno datano data
Lynne Weedall
Senior Independent Non-Executive Director4.5yrsUK£101.00k0.0048%
£ 36.9k
Paul Mason
Chair of the Board9.8yrsUK£342.00k0.81%
£ 6.3m
3.3yrs
Average Tenure
55yo
Average Age

Experienced Board: DOCS's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/22 05:53
End of Day Share Price 2025/07/22 00:00
Earnings2025/03/30
Annual Earnings2025/03/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dr. Martens plc is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard TaylorBarclays
Anne CritchlowBerenberg
David RouxBofA Global Research